

University of Dundee

**Measurement of faecal haemoglobin with a faecal immunochemical test can assist in defining which patients attending primary care with rectal bleeding require urgent referral**

Digby, Jayne; Strachan, Judith A.; McCann, Rebecca; Steele, Robert J. C.; Fraser, Callum G.; Mowat, Craig

*Published in:*  
Annals of Clinical Biochemistry

*DOI:*  
[10.1177/0004563220935622](https://doi.org/10.1177/0004563220935622)

*Publication date:*  
2020

*Document Version*  
Peer reviewed version

[Link to publication in Discovery Research Portal](#)

*Citation for published version (APA):*

Digby, J., Strachan, J. A., McCann, R., Steele, R. J. C., Fraser, C. G., & Mowat, C. (2020). Measurement of faecal haemoglobin with a faecal immunochemical test can assist in defining which patients attending primary care with rectal bleeding require urgent referral. *Annals of Clinical Biochemistry*, 57(4), 325-327. <https://doi.org/10.1177/0004563220935622>

**General rights**

Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

**Take down policy**

If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

# Annals of Clinical Biochemistry

**Measurement of faecal haemoglobin with a faecal immunochemical test (FIT) can assist in defining which patients attending primary care with rectal bleeding require urgent referral.**

Journal:	<i>Annals of Clinical Biochemistry</i>
Manuscript ID	ACB-20-056.R1
Manuscript Type:	Short Report
Date Submitted by the Author:	03-May-2020
Complete List of Authors:	Digby, Jayne; University of Dundee School of Medicine, Centre for Research into Cancer Prevention and Screening Strachan, Judith; NHS Tayside, Blood Sciences; Kings Cross Hospital, Scottish Bowel Screening Centre McCann, Rebecca; Victoria Hospital, Clinical Biochemistry Steele, Robert; University of Dundee, Centre for Research into Cancer Prevention and Screening Fraser, Callum; University of Dundee, Centre for Research into Cancer Prevention and Screening Mowat, Craig; Ninewells Hospital, Gastroenterology
Keywords:	Cancer < Clinical studies

SCHOLARONE™  
Manuscripts

Digby, J., Strachan, J. A., McCann, R. K., Steele, R. J. C., Fraser, C. G., & Mowat, C. (2020). ANNALS EXPRESS: Measurement of faecal haemoglobin with a faecal immunochemical test (FIT) can assist in defining which patients attending primary care with rectal bleeding require urgent referral. *Annals of Clinical Biochemistry*. DOI: <https://doi.org/10.1177/0004563220935622>.

1  
2  
3 **Short Report**  
4  
5  
6  
7

8 **Measurement of faecal haemoglobin with a faecal immunochemical test (FIT)**  
9  
10 **can assist in defining which patients attending primary care with rectal**  
11  
12 **bleeding require urgent referral.**  
13  
14

15  
16  
17 **Jayne Digby,<sup>1</sup> Judith A Strachan,<sup>3</sup> Rebecca McCann,<sup>4</sup> Robert JC Steele,<sup>1</sup>**  
18  
19 **Callum G Fraser<sup>1</sup> and Craig Mowat <sup>2</sup>**  
20  
21

22  
23  
24 <sup>1</sup>Centre for Research into Cancer Prevention and Screening, University of Dundee,  
25  
26 Ninewells Hospital and Medical School, Dundee, Scotland, UK.  
27

28  
29  
30 <sup>2</sup>Department of Gastroenterology, Ninewells Hospital and Medical School, Dundee,  
31  
32 Scotland, UK.  
33

34  
35  
36  
37 <sup>3</sup>Department of Blood Sciences, Ninewells Hospital and Medical School, Dundee,  
38  
39 Scotland, UK.  
40

41  
42  
43  
44 <sup>4</sup>Department of Blood Sciences, Ninewells Hospital and Medical School, Dundee,  
45  
46 Scotland, UK.  
47

48  
49  
50  
51 **Correspondence to:** Dr Jayne Digby, Centre for Research into Cancer Prevention  
52  
53 and Screening, University of Dundee, Ninewells Hospital and Medical School,  
54  
55 Dundee DD1 9SY, Scotland, UK.  
56  
57  
58  
59  
60

1  
2  
3 **E-mail:** [jaynedigby@nhs.net](mailto:jaynedigby@nhs.net) **Telephone:** 01382660111  
4  
5  
6

7 **Short title:** Rectal bleeding and faecal haemoglobin  
8  
9

10  
11  
12 **No of words, abstract:** 247  
13

14 **No of words, text:** ~~967873~~  
15

16  
17 **No of figures:** 0  
18

19 **No of tables:** 1  
20

21 **No of references:** 6  
22  
23

24  
25  
26 **Keywords:** adenoma, colorectal cancer, colorectal disease, faecal haemoglobin,  
27  
28 faecal immunochemical test, inflammatory bowel disease, primary care, rectal  
29  
30 bleeding  
31  
32

33  
34  
35 **Abbreviations:** CRC: colorectal cancer, f-Hb: faecal haemoglobin concentration,  
36  
37 FIT: faecal immunochemical test for haemoglobin, GP: general practitioner, HRA:  
38  
39 higher-risk adenoma, IBD: inflammatory bowel disease, NICE: National Institute for  
40  
41 Health and Care Excellence, SBD: significant bowel disease  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Abstract

## Background

Current guidelines document persistent rectal bleeding as an alarm symptom in patients presenting to primary care. We studied whether a faecal immunochemical test (FIT) could assist in their assessment.

## Methods

From December 2015, FIT were routinely available to Primary Care when assessing patients with new-onset bowel symptoms: general practitioners (GP) were encouraged to include faecal haemoglobin concentration (f-Hb) within any referral to Secondary Care. Results with f-Hb  $\geq 10$   $\mu\text{g}$  Hb/g faeces were defined as positive. The incidence of significant bowel disease (SBD: colorectal cancer [CRC], higher-risk adenoma [HRA: any  $> 1$  cm, or 3 or more] and inflammatory bowel disease [IBD]) at subsequent colonoscopy, referred symptoms, and f-Hb were recorded.

## Results

Of 1,447 patients with a FIT result and colonoscopy outcome, SBD was diagnosed in 296 patients (20.5%; 95 with CRC, 133 with HRA, and 68 with IBD). 462 patients (31.9%) reported rectal bleeding: 294 had f-Hb  $\geq 10$   $\mu\text{g}$  Hb/g faeces. At colonoscopy, 105/294 had SBD versus 14/168 with rectal bleeding and f-Hb  $< 10$   $\mu\text{g}$  Hb/g faeces ( $p < 0.0001$ ), comprising one case of CRC (0.6%), 12 HRA (7.1%), and one new case

1  
2  
3 of IBD (0.6%); further, the single cancer and eight of the 12 HRA were located in the  
4  
5 descending colon.  
6  
7  
8  
9  
10

## 11 **Conclusion**

12  
13  
14  
15 Patients with rectal bleeding and f-Hb <10 µg Hb/g faeces are unlikely to have SBD  
16  
17 and could be investigated by sigmoidoscopy alone. Using FIT to guide investigation  
18  
19 of patients with rectal bleeding is a rational and practical way forward.  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Introduction

Rectal bleeding can be a symptom of underlying colorectal disease and convention dictates that, as such, potential cancer must be considered. The National Institute for Health and Care Excellence (NICE) guideline NG12 states: “Refer adults using a suspected cancer pathway referral for colorectal cancer (CRC) if aged 50 and over with unexplained rectal bleeding ...and consider referral for CRC in adults aged under 50 with rectal bleeding and unexplained ...abdominal pain, change in bowel habit, weight loss, or iron-deficiency anaemia”.<sup>1</sup> The Scottish guidelines also recommend urgent referral for “repeated rectal bleeding without an obvious anal cause”.<sup>2</sup>

Measurement of faecal haemoglobin concentration (f-Hb) with a faecal immunochemical test (FIT) has been advocated as a good rule-out test for significant bowel disease (SBD)<sup>3</sup>. NICE Diagnostics Guidance (DG30) recommends the use of faecal immunochemical tests for haemoglobin (FIT) at a threshold of <10 µg Hb/g faeces, but only in “people *without* rectal bleeding but with unexplained symptoms that do not meet the criteria for a suspected cancer pathway referral”.<sup>4</sup> However, patients reporting rectal bleeding may not have detectable f-Hb: we reported that rectal bleeding symptoms associated with *undetectable* f-Hb carries a low risk of SBD.<sup>5</sup>). We determined whether using FIT with a cut-off of <10 µg Hb/g faeces could assist in the assessment of patients presenting to primary care with rectal bleeding.

## Methods

1  
2  
3  
4  
5  
6 The methods used have been previously detailed.<sup>5</sup> In summary, from December  
7  
8 2015, quantitative FIT analysis was available to primary care. If patients presented  
9  
10 with new-onset lower bowel symptoms, general practitioners (GP) were  
11  
12 recommended to request f-Hb. Patients were instructed to collect a single sample of  
13  
14 faeces and to return the FIT device immediately to the GP surgery and they were  
15  
16 then delivered to Blood Sciences, Ninewells Hospital and Medical School, Dundee.  
17  
18 Analysis was performed on one HM-JACKarc analyser (Hitachi Chemical  
19  
20 Diagnostics Systems Co., Ltd, Tokyo, Japan). Results with f-Hb  $\geq 10$   $\mu\text{g Hb/g}$  faeces  
21  
22 were defined as positive. Patients referred to endoscopy were investigated within six  
23  
24 weeks of referral. Any diagnosis of significant bowel disease (SBD: colorectal cancer  
25  
26 [CRC], higher-risk adenoma [HRA: any > 1 cm, or 3 or more] and inflammatory  
27  
28 bowel disease [IBD]) was confirmed by a consultant pathologist. The symptoms  
29  
30 reported by GPs on patient referral forms submitted to secondary care were  
31  
32 collected to allow a subgroup of those reporting rectal bleeding to be defined.  
33  
34 Clinical outcomes of those reporting rectal bleeding were compared between those  
35  
36 with f-Hb above and those below the f-Hb cut-off of 10  $\mu\text{g Hb/g}$  faeces. Chi-square  
37  
38 tests were performed using MedCalc statistical software (MedCalc Software,  
39  
40 Mariakerke, Belgium).  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50

## 51 Results

52  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 Of 1,447 patients with a f-Hb and colonoscopy outcome seen in the first year of the  
4 service, SBD was diagnosed in 296 patients (20.5%; 95 with CRC, 133 with HRA  
5 and 68 with IBD). 667 (46.1%) of the 1,447 had f-Hb <10 µg Hb/g faeces.  
6  
7  
8  
9

10  
11  
12  
13  
14 462 of investigated patients (31.9%) reported rectal bleeding as a symptom, of whom  
15  
16 2934 had f-Hb ≥10 µg/g faeces. At colonoscopy, 105/2934 (35.7%) patients with  
17  
18 rectal bleeding and f-Hb ≥10 µg/g faeces had SBD versus 14/168 (8.3%) with rectal  
19  
20 bleeding and f-Hb <10 µg Hb/g faeces (p < 0.0001) (Table 1). In the patients with  
21  
22 rectal bleeding and f-Hb ≥10 µg/g faeces, there were 25 cases of CRC (8.5%), 39  
23  
24 HRA (13.3%), and 25 cases of IBD (14.0%). In contrast, of the 168 patients with  
25  
26 rectal bleeding and a f-Hb <10 µg Hb/g faeces, there was one case of CRC (0.6%),  
27  
28 12 HRA (7.1%), and one new case of IBD (0.6%); further, the single cancer and  
29  
30 eight of the 12 HRA were found in the descending colon.  
31  
32  
33  
34  
35  
36  
37  
38

39 ~~Clearly, r~~Rectal bleeding with f-Hb <10 µg Hb/g faeces is associated with a very low  
40  
41 yield of SBD. Further, in this cohort, the clear majority of the SBD could have been  
42  
43 detected by sigmoidoscopy alone, missing only four HRA.  
44  
45  
46  
47  
48  
49

50 If patients with rectal bleeding and f-Hb <10 µg Hb/g faeces had been triaged to  
51  
52 sigmoidoscopy rather than full colonoscopy, this would have saved endoscopy  
53  
54 resource without detriment to the patient; if a colonoscopy equates to two points of  
55  
56 endoscopy time, and a sigmoidoscopy one point of endoscopy time, then 168 units  
57  
58  
59  
60

1  
2  
3 would have been saved over the year. Even more could be saved by watching and  
4  
5 waiting those patients with irregular symptoms.  
6  
7  
8  
9

## 10 11 Discussion

12  
13  
14  
15  
16  
17  
18 FIT have been recommended for the assessment of patients presenting in primary  
19  
20 care with lower bowel symptoms:<sup>3,4</sup> ~~Moreover, f-Hb~~ is the most important factor to be  
21  
22 considered when deciding which patients would benefit most from referral.<sup>6</sup>  
23

24 ~~Further, and~~ a low f-Hb can be used in primary care as a rule-out test to exclude  
25  
26 SBD.<sup>3-5</sup> However, rectal bleeding, with or without other lower bowel symptoms, is  
27  
28 generally considered as a “red flag” symptom,<sup>1,2</sup> requiring urgent referral,  
29  
30 irrespective of the f-Hb. Here, we have shown that patients reported to have rectal  
31  
32 bleeding are unlikely to have SBD if f-Hb <10 µg Hb/g faeces. In contrast, more than  
33  
34 one-third of such patients with f-Hb >10 µg Hb/g faeces had SBD.  
35  
36  
37  
38  
39  
40  
41  
42

43 Patients presenting with rectal bleeding harbour real fears and need an explanation.  
44  
45 They require an objective assessment; a full history, clinical examination, and a full  
46  
47 blood count are essential. We have shown that ~~a FIT test can~~ could provide further  
48  
49 objective evidence of the risk of underlying SBD. Furthermore, we have  
50  
51 demonstrated that, in the presence of a f-Hb <10 µg Hb/g faeces, patients with  
52  
53 persistent rectal bleeding can be safely investigated by sigmoidoscopy alone thereby  
54  
55 enabling more efficient use of endoscopy resources. Safety-netting measures  
56  
57 should also be in place for these patients if they continue to experience rectal  
58  
59  
60

1  
2  
3 bleeding and/or other symptoms due to the small chance that SBD may not be  
4 detected at sigmoidoscopy. Our results indicate that using FIT to guide investigation  
5  
6  
7  
8 of patients with rectal bleeding is a rational and practical way forward and that  
9  
10 current referral guidelines require further attention.  
11  
12  
13  
14  
15

## 16 **Acknowledgements**

17  
18  
19  
20  
21 Lynne Taylor, Department of Blood Sciences, Ninewells Hospital and Medical  
22  
23 School, Dundee, made up and distributed FIT kits to GP practices. Alpha  
24  
25 Laboratories Ltd, Eastleigh, Hants, are thanked for their support for the laboratory  
26  
27 analyses.  
28  
29  
30  
31

## 32 **Declaration of conflicting interests**

33  
34  
35  
36  
37 The author(s) declared the following potential conflicts of interest with respect  
38  
39 to the research, authorship, and/or publication of this article: CGF has undertaken  
40  
41 paid consultancy with Immunostics Inc., Ocean, NJ, USA, and Hitachi Chemical  
42  
43 Diagnostics Systems, Co., Ltd, Tokyo, Japan, and has received support for  
44  
45 attendance at conferences from Alpha Labs Ltd, Eastleigh, Hants, UK. Other authors  
46  
47 have no interests to declare.  
48  
49  
50  
51

## 52 **Funding**

53  
54  
55 The author(s) disclosed receipt of the following financial support for the  
56  
57 research, authorship, and/or publication of this article: This study was  
58  
59 funded by a grant from the Chief Scientist Office (grant number ASM/14/4).  
60

## Ethical approval

The study was approved by the North of Scotland Research Ethics Committee (reference number 15/NS/0101).

## Guarantor

JD.

## Contributorship

JD, JAS, CM, RJCS and CGF conceived and planned the study. JAS supervised, and RMcC undertook, the FIT analyses. JD and CGF performed the data analysis. CM, CGF and JD prepared drafts of the article. All authors contributed significantly to interpretation of the data and to the writing of the article.

## References

1. National Institute for Health and Care Excellence. NICE Guideline NG12; Suspected cancer: recognition and referral. July 2017. [www.nice.org.uk/guidance/ng12](http://www.nice.org.uk/guidance/ng12) (accessed 9 November 2019).
2. National Health Service Scotland. Scottish Referral Guidelines for Suspected Cancer <http://www.cancerreferral.scot.nhs.uk/> (accessed 9 November 2019)

1  
2  
3 3. National Institute for Health and Care Excellence. NICE Diagnostic  
4 Guidance DG 30. July 2017. Quantitative faecal immunochemical tests  
5  
6 to guide referral for colorectal cancer in primary care, [www.nice.org.uk/  
7  
8  
9  
10 guidance/dg30](http://www.nice.org.uk/guidance/dg30) (accessed 9 November 2019).  
11

12  
13  
14 4. Westwood M, Lang S, Armstrong N, et al. Faecal immunochemical tests (FIT) can  
15 help to rule out colorectal cancer in patients presenting in primary care with lower  
16 abdominal symptoms: a systematic review conducted to inform new NICE DG30  
17 diagnostic guidance. *BMC Med.* 2017;**15**:189.  
18  
19

20  
21  
22 5. Mowat C, Digby J, Strachan JA, McCann R, et al. Impact of introducing a faecal  
23 immunochemical test (FIT) for haemoglobin into primary care on the outcome of  
24 patients with new bowel symptoms: a prospective cohort study. *BMJ Open  
25  
26  
27  
28  
29  
30  
31  
32  
33 Gastroenterol* 2019;**6**:e000293.  
34  
35

36  
37 6. Digby J, Steele RJ, Strachan JA, et al. Do other variables add value to  
38 assessment of the risk of colorectal disease using faecal immunochemical tests for  
39 haemoglobin? *Ann Clin Biochem* 2019;**56**:472-9.  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

**Table 1.** Prevalence of significant bowel disease (SBD), encompassing colorectal cancer (CRC), higher-risk adenoma (HRA) and inflammatory bowel disease (IBD) in patients with rectal bleeding stratified by faecal haemoglobin concentration (f-Hb).

	All patients		f-Hb <10 µg Hb/g faeces and rectal bleeding		f-Hb ≥10 µg Hb/g faeces and rectal bleeding		p-value*
	n	%	n	%	n	%	
No of colonoscopies	1447		168		293		
No with CRC	95	6.6	1	0.6	25	8.5	<0.001
No with HRA	133	9.2%	12	7.1	39	13.3	0.424
No with IBD	68	4.7%	1	0.6	410	13.714.0	<0.0001
Total SBD (CRC + HRA +IBD)	296	20.5	14	8.3	105	35.8	<0.0001

\* p-value is for comparison of those with f-Hb <10 µg Hb/g faeces and ≥10 µg Hb/g faeces who had rectal bleeding.